AMP® Symposium Day 1: Alzheimer's Disease

The Accelerating Medicines Partnership® (AMP®) Program Alzheimer’s disease (AMP AD 2.0) is a precompetitive public-private partnership that will enable precision medicine research for Alzheimer’s disease through deep and longitudinal molecular analyses across diverse populations to provide insights that will accelerate the development of therapies for Alzheimer’s disease.
This multisector partnership, managed by the Foundation for the NIH, will focus on providing a data-driven approach for identification and validation of biomarkers that will lead to increased clinical trial success.
AMP AD 2.0 builds on the success of AMP AD 1.0 and joins a portfolio of AMP programs that use cutting-edge scientific approaches to bring new medicines and support to patients by enhancing validation of novel, clinically relevant therapeutic targets and biomarkers.
The Accelerating Medicines Partnership® (AMP®) Program was launched in February 2014 to bring together the resources and expertise of both the National Institutes of Health (NIH) and the private sector to solve pressing challenges in various diseases and disease areas. The AMP program, managed by the FNIH, is comprised of projects with a common goal of accelerating the process of bringing new and effective therapies to patients and operates under the broad principle of delivering pre-competitive advancements to the research and medical fields to enable broad access and use of AMP research discoveries. Originally focused on three specific diseases, the program has since grown to 10 individual projects representing the contributions and participation of 16 NIH institutes and over 70 private sector partners.
This inaugural scientific symposium celebrated the 10th anniversary of the program, highlighted successful innovation and collaboration in each of the individual AMP project areas, and provided a forum for discussions and cross-collaboration in the broader AMP research community.
fnih.org/our-p...